PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26024F0401Iclusig 30mg TABS — Takeda Pharmaceuticals America, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended May 9, 2025 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Takeda Pharmaceuticals America, Inc

Recipient

May 9, 2025

PoP end

$174K

Obligated

$174K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Takeda Pharmaceuticals America, Inc — $90

Contract facts

Federal

Contract number36C26024F0401

Also listed as36C260-24-F-0401

Also listed as36F79718D0586-36C26024F0401

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentTakeda Pharmaceuticals America, Inc

CAGE3FLV7

UEIENNFDLWFC6L1

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79718D0586

Place of performanceEARTH CITY MO

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startMay 10, 2024

PoP end (current)May 9, 2025

Obligated$174K

Current value$174K

Potential value$174K

ICLUSIG 30MG TABS is a federal award for 260-Network Contract Office 20 (36C260) held by Takeda Pharmaceuticals America, Inc. Estimated value $174K ($174K obligated). Current period of performance ends May 9, 2025. Last award drew 1 bidder. Place of performance: EARTH CITY MO.

Recompete timing

Public

● Past PoP end (469 days ago)

Current PoP ended May 9, 2025 (469 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26024F0401?

36C26024F0401 (Iclusig 30mg TABS) is a 260-Network Contract Office 20 (36C260) award with a potential value of $174K, currently held by Takeda Pharmaceuticals America, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-24-F-0401?

36C260-24-F-0401 is the dashed form of PIID 36C26024F0401 (Iclusig 30mg TABS), held by Takeda Pharmaceuticals America, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26024F0401?

260-Network Contract Office 20 (36C260) awarded 36C26024F0401 to Takeda Pharmaceuticals America, Inc (potential $174K).

Who is the incumbent on 36C26024F0401?

Takeda Pharmaceuticals America, Inc is the incumbent. The current period of performance ends May 9, 2025.

When does Takeda Pharmaceuticals America, Inc’s 36C26024F0401 come up for recompete?

SCOUT tracks a period-of-performance end of May 9, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 25, 2025 · refreshed monthly